JP2009500347A - ビスアリールキナーゼ阻害剤及びこれらの炎症、血管新生及び癌の治療における使用 - Google Patents

ビスアリールキナーゼ阻害剤及びこれらの炎症、血管新生及び癌の治療における使用 Download PDF

Info

Publication number
JP2009500347A
JP2009500347A JP2008519634A JP2008519634A JP2009500347A JP 2009500347 A JP2009500347 A JP 2009500347A JP 2008519634 A JP2008519634 A JP 2008519634A JP 2008519634 A JP2008519634 A JP 2008519634A JP 2009500347 A JP2009500347 A JP 2009500347A
Authority
JP
Japan
Prior art keywords
compound
mmol
groups
mammal
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008519634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009500347A5 (https=
Inventor
キム，テ−ソン
アルマンジユ，ジヤン−クリストフ
ブツカー，シヨン
ダンジエロ，ノエル
ドミンゲス，セリア
フエローズ，イングリツド・エム
リウ，ロンピン
タスカー，アンドリユー
ベロン，ステイーブン
ハーベイ，テイモシー・エス
リー，マシユー
ジエルマン，ジユリー
パテル，ビノツド・エフ
キム，ジヨセフ・エル
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2009500347A publication Critical patent/JP2009500347A/ja
Publication of JP2009500347A5 publication Critical patent/JP2009500347A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP2008519634A 2005-06-30 2006-06-29 ビスアリールキナーゼ阻害剤及びこれらの炎症、血管新生及び癌の治療における使用 Pending JP2009500347A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69638905P 2005-06-30 2005-06-30
PCT/US2006/025699 WO2007005668A2 (en) 2005-06-30 2006-06-29 Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer

Publications (2)

Publication Number Publication Date
JP2009500347A true JP2009500347A (ja) 2009-01-08
JP2009500347A5 JP2009500347A5 (https=) 2009-12-10

Family

ID=37395970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008519634A Pending JP2009500347A (ja) 2005-06-30 2006-06-29 ビスアリールキナーゼ阻害剤及びこれらの炎症、血管新生及び癌の治療における使用

Country Status (7)

Country Link
US (1) US8017601B2 (https=)
EP (1) EP1896461A2 (https=)
JP (1) JP2009500347A (https=)
AU (1) AU2006265835B2 (https=)
CA (1) CA2611688A1 (https=)
MX (1) MX2007015679A (https=)
WO (1) WO2007005668A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017507177A (ja) * 2014-02-24 2017-03-16 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズＳｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ ナフチルアミド系化合物、その製造方法および使用
JP2022009994A (ja) * 2015-06-25 2022-01-14 大鵬薬品工業株式会社 線維症治療剤

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
AU2008335709A1 (en) * 2007-12-13 2009-06-18 Amgen Inc. Gamma secretase modulators
EP2300427A1 (en) * 2008-05-05 2011-03-30 Amgen Inc. Urea compounds as gamma secretase modulators
US8512695B2 (en) 2008-10-21 2013-08-20 The General Hospital Corporation Method of preventing fat graft resorption by administering fat-derived cells and poloxamer P 188
WO2012002577A1 (ja) 2010-06-30 2012-01-05 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
WO2012019103A2 (en) 2010-08-06 2012-02-09 The General Hospital Corporation D/B/A System and apparatus for cell treatment
KR101886459B1 (ko) 2010-10-08 2018-08-07 니발리스 테라퓨틱스, 인코포레이티드 S-나이트로소글루타티온 리덕타제 억제제로서의 신규한 치환된 퀴놀린 화합물
JP5898230B2 (ja) 2010-12-16 2016-04-06 ニヴァリス・セラピューティクス・インコーポレーテッド Ｓ−ニトロソグルタチオンレダクターゼ阻害薬としての新規な置換二環芳香族化合物
DE102012017739A1 (de) * 2012-09-07 2014-03-13 Clariant International Ltd. Verfahren zur Herstellung von N-substituierten Pyrrolidoncarbonsäureestern
US9284310B2 (en) 2012-11-03 2016-03-15 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
CN106029076B (zh) 2013-11-18 2019-06-07 福马疗法公司 作为bet溴域抑制剂的苯并哌嗪组合物
JP6553632B2 (ja) 2013-11-18 2019-07-31 フォーマ セラピューティクス，インコーポレイテッド Ｂｅｔブロモドメイン阻害剤としてのテトラヒドロキノリン組成物
NO2699580T3 (https=) 2014-01-24 2018-02-24
US20150252022A1 (en) * 2014-03-10 2015-09-10 Innov17 Llc Retinoic acid receptor-related orphan receptor modulators and uses thereof
US20160024086A1 (en) * 2014-07-25 2016-01-28 Innov17 Llc Azaindole retinoic acid receptor-related orphan receptor modulators and uses thereof
WO2016014910A1 (en) * 2014-07-25 2016-01-28 Innov17 Llc Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof
US20160024052A1 (en) * 2014-07-25 2016-01-28 Innov17 Llc Benzimidazole retinoic acid receptor-related orphan receptor modulators and uses thereof
US9884847B2 (en) 2014-07-25 2018-02-06 Innov17 Llc Indazole retinoic acid receptor-related orphan receptor modulators and uses thereof
ES2730112T3 (es) 2015-03-09 2019-11-08 Bristol Myers Squibb Co Lactamas como inhibidores de ROCK
WO2017044766A1 (en) 2015-09-10 2017-03-16 Nivalis Therapeutics, Inc. Solid forms of an s-nitrosoglutathione reductase inhibitor
CN106543145B (zh) * 2016-10-28 2019-07-19 山西医科大学 c-Met激酶抑剂3-(4-氟苯基)嘧啶酮-5-甲酸酰胺衍生物、制备方法与应用
US11555009B2 (en) 2017-03-02 2023-01-17 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences 2-(substituted benzene matrix) aromatic formate FTO inhibitor, preparation method therefor, and applications thereof
KR20250002710A (ko) 2018-03-01 2025-01-07 아스트라제네카 에이비이 (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를포함하는 약학 조성물
KR102803660B1 (ko) 2018-03-05 2025-05-02 브리스톨-마이어스 스큅 컴퍼니 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제
AU2019306532A1 (en) 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
CA3125900A1 (en) 2019-01-08 2020-07-16 Kyorin Pharmaceutical Co., Ltd. 15-pgdh inhibitor
US12304897B2 (en) 2019-01-31 2025-05-20 Kyorin Pharmaceutical Co., Ltd. 15-PGDH inhibitors
AU2021348477B2 (en) * 2020-09-23 2023-12-21 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Csf1r kinase inhibitor and use thereof
EP4646265A1 (en) 2023-01-06 2025-11-12 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07502762A (ja) * 1992-10-23 1995-03-23 セルテック　リミテッド 三置換フェニル誘導体およびそれらの製造方法
WO2000047212A1 (en) * 1999-02-10 2000-08-17 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
WO2005049577A1 (en) * 2003-11-19 2005-06-02 Glaxo Group Limited 1-amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5
WO2005049576A1 (en) * 2003-11-19 2005-06-02 Glaxo Group Limited Substitute isoquinolines useful in the treatment of diseases such as cancer and atherosclerosis
JP2005255981A (ja) * 2004-02-12 2005-09-22 Chisso Corp ジアミン、ポリマー、液晶配向膜および液晶表示素子

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656643A (en) * 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6143764A (en) * 1995-11-07 2000-11-07 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
US6462064B1 (en) * 1996-07-08 2002-10-08 Galderma Research & Development S.N.C. Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias
WO2001030764A1 (en) * 1999-10-22 2001-05-03 Takeda Chemical Industries, Ltd. 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof
DE60137273D1 (de) * 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
EP2258366B1 (en) * 2001-06-22 2013-04-03 Kirin Pharma Kabushiki Kaisha Quinoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07502762A (ja) * 1992-10-23 1995-03-23 セルテック　リミテッド 三置換フェニル誘導体およびそれらの製造方法
WO2000047212A1 (en) * 1999-02-10 2000-08-17 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
WO2005049577A1 (en) * 2003-11-19 2005-06-02 Glaxo Group Limited 1-amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5
WO2005049576A1 (en) * 2003-11-19 2005-06-02 Glaxo Group Limited Substitute isoquinolines useful in the treatment of diseases such as cancer and atherosclerosis
JP2005255981A (ja) * 2004-02-12 2005-09-22 Chisso Corp ジアミン、ポリマー、液晶配向膜および液晶表示素子

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
AHLBRECHT, SYNTHESIS, vol. N3, JPN5008009609, March 1983 (1983-03-01), pages 231 - 234, ISSN: 0002148394 *
BONNIER, TETRAHEDRON LETTERS, vol. V7, JPN5008009614, 1967, pages 627 - 630, ISSN: 0002148397 *
FISCHER-DURAND, SYNTHETIC COMMUNICATIONS, vol. V28 N6, JPN5008009601, 1998, pages 963 - 970, ISSN: 0002148389 *
HEY, JOURNAL OF THE CHEMICAL SOCIETY, JPN5008009617, 1940, pages 374 - 383, ISSN: 0002148387 *
HIROMI OKUSHIMA, JOURNAL OF MEDICINAL CHEMISTRY, vol. V30 N7, JPN5008009606, 1987, US, pages 1157 - 1161, ISSN: 0002148392 *
J.JIA, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. V14 N5, JPN5008009599, 2004, pages 1221 - 1227, ISSN: 0002148388 *
MILTON J.KORNET, JOURNAL OF PHARMACEUTICAL SCIENCES, vol. V68 N3, JPN5008009611, March 1979 (1979-03-01), pages 350 - 353, ISSN: 0002148395 *
MUELLER-WESTERHOFF, TETRAHEDRON, vol. V47 N6, JPN5008009604, 1991, pages 909 - 932, ISSN: 0002148391 *
NAZAROV, IZV.AKAD.NAUK SSSR SER.KHIM., JPN5008009616, 1956, pages 567 - 572, ISSN: 0002148398 *
SHEINKMAN, CHEM.HETEROCYCL.COMPD., vol. V6, JPN5008009612, 1970, pages 1413 - 1419, ISSN: 0002148396 *
TAKAHASHI, SYNTHESIS, vol. N6/7, JPN5008009607, June 1985 (1985-06-01), pages 690 - 691, ISSN: 0002148393 *
TEN HAVE R, TETRAHEDRON, vol. V53 N33, JPN5008009602, 18 August 1997 (1997-08-18), NL, pages 11355 - 11368, ISSN: 0002148390 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017507177A (ja) * 2014-02-24 2017-03-16 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズＳｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ ナフチルアミド系化合物、その製造方法および使用
JP2022009994A (ja) * 2015-06-25 2022-01-14 大鵬薬品工業株式会社 線維症治療剤
JP7258985B2 (ja) 2015-06-25 2023-04-17 大鵬薬品工業株式会社 線維症治療剤
US11690838B2 (en) 2015-06-25 2023-07-04 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for fibrosis

Also Published As

Publication number Publication date
AU2006265835B2 (en) 2012-05-03
EP1896461A2 (en) 2008-03-12
WO2007005668A2 (en) 2007-01-11
CA2611688A1 (en) 2007-01-11
US8017601B2 (en) 2011-09-13
MX2007015679A (es) 2008-02-21
US20070054903A1 (en) 2007-03-08
AU2006265835A1 (en) 2007-01-11
WO2007005668A3 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
JP5528812B2 (ja) 複素環式化合物ならびに炎症、血管形成および癌の治療におけるこれらの使用
AU2006265835B2 (en) Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
AU2007338792B2 (en) Substituted heterocycles and methods of use
JP4932495B2 (ja) 化合物及び使用方法
AU2007338795B2 (en) Substituted heterocycles and methods of use
AU2008219166B2 (en) Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
JP5463033B2 (ja) タンパク質キナーゼ阻害薬としての置換アミド誘導体
ES2450566T3 (es) Análogos de quinazolina y quinolinas y su uso como medicamentos para tratar el cáncer
AU2008205252B2 (en) Bis-aryl amide derivatives useful for the treatment of cancer
ES2391386T3 (es) Derivados de pirrolopiridina para el tratamiento de enfermedades cancerosas
MX2007000672A (es) Derivados de arilamina sustituida y metodos de uso.
MX2010012528A (es) Heterociclos como inhibidores de proteina cinasa.
MXPA06008327A (en) Compounds and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120214

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120510

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120911

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130226